january, 2021
07janAll Day13febJOIN MCDERMOTT & EY AT THE 2021 J.P. MORGAN HEALTHCARE CONFERENCE
Event Details
You won’t want to miss four days of exclusive, virtual events that bring together industry leaders, emerging standouts, innovators and investors from across the industry landscape at the largest healthcare
Event Details
You won’t want to miss four days of exclusive, virtual events that bring together industry leaders, emerging standouts, innovators and investors from across the industry landscape at the largest healthcare investment symposium.
Healthcare leaders will address comprehensive trends and implications faced in Digital Health, Life Sciences, Healthcare Private Equity (PE) and Hospitals and Health Systems (HHS). Develop an effective, long-term strategy through the post-pandemic period while forging deals and funding agreements to impact the industry’s future.
EVENTS
*Registration is complimentary
DIGITAL HEALTH
Join top industry executives for a series of fireside chats on the evolving doctor-patient relationship and the digitized data and technology convergence with healthcare delivery and payment. Gain insight into 2021’s regulatory considerations affecting healthcare innovation and its solutions.
Panelists:
BJ Moore, Executive Vice President and Chief Information Officer, Providence St. Joseph Health
Jodi Rosen, Senior Director, Innovation, Walgreens Boots Alliance
Dr. Ali Parsa, Chief Executive Officer, Babylon Health
2020 was a year like no other as the annual biopharma M&A total fell to the lowest level since EY began publishing its annual M&A Firepower report in 2013. In the first half of the year, the specter of COVID-19 deterred deals; as economies started to reopen, persistently high valuations were another reason many buyers remained on the fence. In the midst of such uncertainty, an innovation narrative emerged, with growing evidence of the power of new technologies, from antibody drug conjugates in oncology to RNA-based vaccines. These new innovations sparked many of 2020’s most notable deals and are sure to be important in the future. In this one hour panel discussion, we will discuss the current state of biopharma dealmaking and its implications for 2021 with M&A leaders from across the industry.
Topics include:
How current high valuations and liquidity play into deal considerations in a COVID and post-COVID world
The continued importance of therapy area focus – and its impact on dealmaking, especially bolt-ons and partnering
How strategic buyers and sellers can work with private equity in the current environment
How M&A and partnering will be used to add capabilities required to deliver care in the home as virtual care becomes the norm
Panelists:
Stefan Oschmann, Chairman and CEO, Merck KGaA, Darmstadt, Germany
John Young, Group President and Chief Business Officer, Pfizer
Elizabeth Mily, EVP, Strategy and Business Development, Bristol Myers Squibb
Moderator:
Peter Behner, Global Health Sciences & Wellness Strategy and Transactions Leader, EY
Well, 2020 was a wild ride. Due to the pandemic, medtech was right in the middle, supplying critical lifesaving technologies such as ventilators and early detection diagnostics and suffering losses as physicians and patients deferred less acute procedures. Medtech M&A for 2020 was light but the sector managed to remain active and 2H20 did produce a few large transactions. With global hospital utilizations continuing to improve month over month and (hopefully) more visibility into 2021 operating results, the medtech M&A market could be poised for a decent rebound and increase going into 2021. The EY/MWE Medtech Panel will focus on the M&A outlook for 2021, including deal considerations and events that could lead to a more cautious outlook or a return to boom times.
Mergers & acquisitions (M&A) leaders from medtech organizations and private equity firms focused on the sector will share insights and best practices for their 2021 plans, including the following:
Impact of the increase in medtech Firepower during 2020, including debt/equity raised by major OEMs
The impact of the liquid capital markets (IPOs, SPACs, etc.) on Medtech M&A
How the broader capital markets environment—cheap credit, activist shareholders—affects resource allocation for transformative M&A
How traditional medtechs will play in the evolving HCIT ecosystem
Panelists:
Christopher Cleary, VP, Corporate Development, Medtronic
Joseph DeVivo, President, Hospital and Health Systems, Teladoc
Kendall Garrison, Partner, TPG
Susan Morano, VP, Business Development, Johnson & Johnson Medical Devices
J.P. Peltier, Global Group Head, Healthcare Investment Banking, Piper Sandler
Moderator:
John Babitt, Partner, Life Sciences, Ernst & Young LLP
The cell and gene therapy (CGT) industry is moving into a truly transformative era. With so many different emerging CGTs on the horizon and the complexities associated with them, the industry needs to become more dynamic and collaborative to accommodate this changing landscape and to achieve scale. We will bring together a panel of industry stakeholders to discuss what could be achieved if data were more easily and appropriately shared amongst all who have a critical role in a patient’s care, and how we might create this trusted environment and associated infrastructure to maintain safety, security, and privacy to enable the speed of science to develop even faster.
Panelists:
Brian Malkin, Partner, FDA Practice, McDermott Will & Emery
Dr. David Rhew, Global Chief Medical Officer (CMO) and VP of Healthcare, Microsoft
Orlando Serani, Program Architect CAR-T Advanced Cell Therapies Supply Chain, Janssen Pharmaceutical Companies of Johnson & Johnson
Moderator:
Adlai Goldberg, Global Life Sciences Digital, Social and Commercial Innovation Leader, EY
Macroeconomic Outlook: Why It Takes a Global Pandemic to Reduce U.S. Healthcare Expenditures
12:15 – 12:35 pm
The macroeconomic impact of COVID-19 and the subsequent recession drove our national healthcare expenditure growth negative for the first time in 60+ years. Hear our speakers discuss the macroeconomic outlook for healthcare and the potential rebound implications for 2021.
Panelists:
Jeff Woods, Managing Director, EY-Parthenon
Nigel Gault, Chief Economist, EY-Parthenon
Election and Policy Implications: Healthcare Regulatory and Policy Outlook with the New Administration
12:35 – 1:15 pm
By mid-January, the Georgia senate race should be completed, along with the Biden administration transition. This seasoned panel of Washington insiders will analyze the policy implications and legislative agenda and its impact on the healthcare industry.
Panelists:
Heather Meade, Principal, Health Care Policy, Washington Council Ernst & Young
Mara McDermott, Vice President, McDermott+Consulting
Brian Fortune, Senior Managing Director, Farragut Square Group
Thomas Scully, General Partner, Welsh, Carson, Anderson, and Stowe
Moderator:
Eric Zimmerman, Global Head of Health, McDermott Will & Emery
Recent private equity activity has involved collaborations and partnerships with health systems in numerous ways, and this trend is likely to continue. Private equity is increasingly investing in entire health systems, exiting investments by selling to health systems, purchasing a division of a health system as either a platform or portfolio company add-on and engaging in other innovative joint ventures. Listen to our panelists discuss the how and why of the evolution of these partnerships and what the future holds for these creative deal structures.
Leading professionals from across the industry will discuss how to position your organization to innovate, collaborate and grow in this dynamic environment as today’s hospital and health system market faces new levels of disruption. New this year, hear how Chief Executive Officers are focusing on strategic business priorities in 2021 and beyond, during our CEO panel.
Leading professionals will forecast critical legal, regulatory and financial trends facing hospitals and health systems and offer insight on how to position your organization to innovate, collaborate and grow in this dynamic environment.
Panelists:
Matthew Weiss, MD, Managing Director, EY-Parthenon
Sandy DiVarco, Partner, McDermott Will & Emery
Jennifer Geetter, Partner, McDermott Will & Emery
Mike J India, Managing Director, EY-Parthenon
Moderator:
Charlie Buck, Partner, McDermott Will & Emery
For questions, please contact McDermott.
Time
January 7 (Thursday) - February 13 (Saturday)
Location
Virtual
Organizer
McDermott Will & Emery